Headquartered within steps of the USPTO with an affiliate office in Tokyo, Oblon is one of the largest law firms in the United States focused exclusively on intellectual property law.
1968
Norman Oblon with Stanley Fisher and Marvin Spivak launched what was to become Oblon, McClelland, Maier & Neustadt, LLP, one of the nation's leading full-service intellectual property law firms.
Outside the US, we service companies based in Japan, France, Germany, Italy, Saudi Arabia, and farther corners of the world. Our culturally aware attorneys speak many languages, including Japanese, French, German, Mandarin, Korean, Russian, Arabic, Farsi, Chinese.
Oblon's professionals provide industry-leading IP legal services to many of the world's most admired innovators and brands.
From the minute you walk through our doors, you'll become a valuable part of a team that fosters a culture of innovation, client service and collegiality.
The United States Patent and Trademark Office (USPTO) issued final rules implementing the inventor's oath or declaration provisions of the America Invents Act (AIA) on August 14, 2012.
Les Nouvelles - Licensing Executives Society International (LESI)
November 11, 2024
October 9-10, 2024 in Tokyo and Osaka
October 1 and 3, 2024
Kevin L. Hartman, Ph.D. is an Associate in the firm’s Chemical Patent Prosecution group, focusing on patent preparation and prosecution for domestic and international clients in a wide range of technical areas including materials, nanotechnology, bioengineering, and medical devices.
Prior to joining the firm, Dr. Hartman worked at Seoul National University in Korea as a researcher to investigate various biosensing applications of nanotechnology. In his doctoral work at the University of California, Berkeley, Dr. Hartman used synthetic lipid membranes to study the binding properties of a classical cell adhesion protein, E-cadherin, and a part of the project was carried out in the Mechanobiology Institute at the National University of Singapore. In the multidisciplinary environment of the institute, Dr. Hartman’s research efforts led to the discovery that active cell processes are required to nucleate E-cadherin junctions.
Throughout Dr. Hartman’s international graduate and post-graduate career, he has additionally assisted scientists from a range of cultures and backgrounds in forming strong, clear arguments backed by their original research data.